Board meeting outcome of Board Meeting held on 3rd November, 2026

Date: 03.11.2026 Department of Corporate Services, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 524748 Dear Sir/Madam, Sub: Outcome of Board Meeting held on 03rd November, 2026. Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of the Company, at its Meeting held today, i.e. Tuesday 03rd November, 2026, inter alia, considered and approved followings: 01. Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 along with the Limited Review Report of the Statutory Auditors. Please find enclosed herewith Unaudited Financial Results along with Limited Review Report for the quarter and half year ended September 30, 2026. The meeting of the Board of Directors commenced at 11:30 A.M and concluded at 12:30 P.M. Kindly take the same on your record. Thanking you, Yours truly, For Link Pharma Chem Limited Komal Bhojwani Company Secretary & Compliance officer Membership No.: A65594 Encl: As above REGISTERED OFFICE: Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India) Tel. (O) 9925057946 E-Mail: linkpharmacs@gmail.com CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in CNK & Associates LLP Chartered Accountants Independent Auditor's Review Report on Unaudited Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Boatd of Directors of Link Pharma Chem Limited 1. We have reviewed the accompanying Statement of Unaudited Financial results of Link Pharma Chem Limited (“the Company”) for the quarter ended 30¢h September, 2026 and the year to date results for the period from 1st April, 2026 to 30th September, 2026 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the “Listing Regulations”). 2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requitements) Regulations, 2015 as amended. Our responsibility is to express a conclusion on the Statements based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain.moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquirics, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘Ind AS’) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement. For CNK & Associates LLP Chartered Accountants Firm Registration No. 101961W/W-100036 Pareen Shah Partner Membership No. 125011 Place: Vadodara Date: 03rd November, 2026 UDIN: 26125011UJQCUQ9753 The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch’s Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483 Website: www.cnkindia.com VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | GURGOON | KOLKATA | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABL @ Lin Pharma Chem Ltd. 1S0-9001-2015 - 1SO-14001-2015 - 1SO-45001-2018 STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER, 2026 (Rs. In Lakhs) Quarter Ended Half Yearly Ended Year Ended s 30th 30th 30th 30th 30th 315t " Iparticulars September June September September | September March No- 2026 2026 , 2025 2026 2025 2026 (Unaudited) | {Unaudited) (Unaudited) | (Unaudited) | (Unaudited) | (Audited) 1 [Revenue from operations 533.13 876.84 629.32 1,409.97 1,410.80 2,743.15 Other income 548 34.89 478 2041 25.70 2034 Total Income (A) 527.65 911.73 634.10 1,439.39 1,436.50 2,763.49 2 |Expenses: Cost of materials consumed 196.23 378.00 257.18 574.24 526.87 1,061.76 Chaangne gin einvseentonri est orieosoff ffiinniisshh ed goods and work-ciinn - 8i58) . (3807 728 o2 - progress Employee benefits expense 147.86 159.26 14139 307.12 202,41 608.75 Finance costs 171 1422 1286 2593 23.26 52.98 Depreciation and amortization expense 28.13 27.42 24.77 5554 48.68 97.99 Power and Fuel 75.20 7911 94.20 154.31 180.56 32331 Other Expenses 11405 158.01 140.55 27207 287.11 591.52 Total expenses (B) 553.63 872.86 632.87 1,026.49 | 1,384.31 2,749.98 3 |(Loss)/Profit before tax (C) = (A-B) (25.57) 38.87 123 12.90 52.19 1351 2 [Tax expense: , (1) Current tax - x : = [2) Deferred tax (3.66) 7.08 033) 3.38 1046 5.82 Total tax expense (D) (3.66) 7.04 (0:33)] 338 10.46 5.82 5 | (Loss)/Profit for the year/period (E) = (C-D) (2231) 3183 156 952 aL73 7.69 6 |Other Comprehensive Income items that will not be reclassified to profiotr loss Net fai value gain on equity instruments through 017 - (005) 0361 R e 006 Other Comprehensive Income Remeasurement (loss) / gaoif nth e defined benefit ohin {loss) / gain of the defined benefl 166 166 -0.65 EE?) (1.30) 6.66 Income tax effect on sbove (©.49) (039) 015 (0.84) 033 (1.68) Total otherc e h ive L Neil amSHAfor rtthheE 105 088 (0.55) 193 (0.70) 5.04 vear/period, net of tax (F) Total hensive i forth i 5 |Total comprehensive income for the year/period (Net (21.26) 2N 100 i1 a0 1273 of Tax) (E+F) 8 |Paid up Equity share capital of Rs 10 each 244.06 444.06 444.06 44405 444.06 44406 9 |Other Equity 834.86 Lo |Earnings per equity share (FV of Rs. 10) (Rs.)(Not annualised) Basic and Diluted 0.50) 072 0,03 021 094 017 /162, G.LD.C., Nandesari - 391340, Dist. Vadodara, (Gujarat), (India). REGISTERED OFFICE : Plot No. Tel. (0) 99250 57946 E-Mail : linkpharmalimited@gmail.com CIN: L24230GJ1984PLC007540 www.linkpharmachem.co.in @ Lin Pharma Chem Ltd. 1S0-9001-2015 - ISO-14001-2015 - 1SO-45001-2018 Notes: 1 AT uh de i ta b Co ov me m ifi tn ta en eci a al n dr e hsu al vt es bf eor e nt h ae p pQ ru oar vt ee dr a a nn dd w H ea rl ef ty ae kar e ne on nd e rd e co on r dS be yp t te hm eb e Br o, a r3 d0 , o f2 D0 i2 r6 e ch ta ov rse ab te ie tn s mr ee ev ti ie nw ge d h eb ly d S ot na t Nu ot vor ey m bau ed ri t 0o 3r ,s , 2 0r 2e 6c ommended by the 2 The Company's opera [Showing first 8,000 characters — download PDF for full document]